Abstract
PTP1B, a validated therapeutic target for diabetes and obesity, has a critical positive role in HER2 signaling in breast tumorigenesis. Efforts to develop therapeutic inhibitors of PTP1B have been frustrated by the chemical properties of the active site. We define a new mechanism of allosteric inhibition that targets the C-terminal, noncatalytic segment of PTP1B. We present what is to our knowledge the first ensemble structure of PTP1B containing this intrinsically disordered segment, within which we identified a binding site for the small-molecule inhibitor MSI-1436. We demonstrate binding to a second site close to the catalytic domain, with cooperative effects between the two sites locking PTP1B in an inactive state. MSI-1436 antagonized HER2 signaling, inhibited tumorigenesis in xenografts and abrogated metastasis in the NDL2 mouse model of breast cancer, validating inhibition of PTP1B as a therapeutic strategy in breast cancer. This new approach to inhibition of PTP1B emphasizes the potential of disordered segments of proteins as specific binding sites for therapeutic small molecules.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Slamon, D.J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).
Tiwari, R.K., Borgen, P.I., Wong, G.Y., Cordon-Cardo, C. & Osborne, M.P. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 12, 419–425 (1992).
Engelman, J.A. & Settleman, J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18, 73–79 (2008).
Rexer, B.N. & Arteaga, C.L. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene–amplified breast cancer: mechanisms and clinical implications. Crit. Rev. Oncog. 17, 1–16 (2012).
Tonks, N.K. Protein tyrosine phosphatases–from housekeeping enzymes to master regulators of signal transduction. FEBS J. 280, 346–378 (2013).
Andersen, J.N. & Tonks, N.K. Protein tyrosine phosphatase-based therapeutics: lessons from PTP1B. Top. Curr. Genet. 5, 201–230 (2004).
Julien, S.G. et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat. Genet. 39, 338–346 (2007).
Bentires-Alj, M. & Neel, B.G. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res. 67, 2420–2424 (2007).
Tonks, N.K., Diltz, C.D. & Fischer, E.H. Purification of the major protein-tyrosine-phosphatases of human placenta. J. Biol. Chem. 263, 6722–6730 (1988).
Hao, L., Tiganis, T., Tonks, N.K. & Charbonneau, H. The noncatalytic C-terminal segment of the T cell protein tyrosine phosphatase regulates activity via an intramolecular mechanism. J. Biol. Chem. 272, 29322–29329 (1997).
Lantz, K.A. et al. Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice. Obesity (Silver Spring) 18, 1516–1523 (2010).
Wiesmann, C. et al. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat. Struct. Mol. Biol. 11, 730–737 (2004).
Metallo, S.J. Intrinsically disordered proteins are potential drug targets. Curr. Opin. Chem. Biol. 14, 481–488 (2010).
Cuchillo, R. & Michel, J. Mechanisms of small-molecule binding to intrinsically disordered proteins. Biochem. Soc. Trans. 40, 1004–1008 (2012).
Pervushin, K., Riek, R., Wider, G. & Wuthrich, K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc. Natl. Acad. Sci. USA 94, 12366–12371 (1997).
Zhang, H., Neal, S. & Wishart, D.S. RefDB: a database of uniformly referenced protein chemical shifts. J. Biomol. NMR 25, 173–195 (2003).
Barford, D., Flint, A.J. & Tonks, N.K. Crystal structure of human protein tyrosine phosphatase 1B. Science 263, 1397–1404 (1994).
Muthuswamy, S.K., Li, D., Lelievre, S., Bissell, M.J. & Brugge, J.S. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat. Cell Biol. 3, 785–792 (2001).
Konecny, G.E. et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2–overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630–1639 (2006).
Siegel, P.M., Dankort, D.L., Hardy, W.R. & Muller, W.J. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol. 14, 7068–7077 (1994).
Dubé, N., Cheng, A. & Tremblay, M.L. The role of protein tyrosine phosphatase 1B in Ras signaling. Proc. Natl. Acad. Sci. USA 101, 1834–1839 (2004).
Julien, S.G., Dube, N., Hardy, S. & Tremblay, M.L. Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer 11, 35–49 (2011).
Sangwan, V. et al. Protein-tyrosine phosphatase 1B modulates early endosome fusion and trafficking of Met and epidermal growth factor receptors. J. Biol. Chem. 286, 45000–45013 (2011).
Brown-Shimer, S. et al. Molecular cloning and chromosome mapping of the human gene encoding protein phosphotyrosyl phosphatase 1B. Proc. Natl. Acad. Sci. USA 87, 5148–5152 (1990).
Tonks, N.K. & Muthuswamy, S.K. A brake becomes an accelerator: PTP1B—a new therapeutic target for breast cancer. Cancer Cell 11, 214–216 (2007).
Wiener, J.R. et al. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J. Natl. Cancer Inst. 86, 372–378 (1994).
Wang, J., Chen, X., Liu, B. & Zhu, Z. Suppression of PTP1B in gastric cancer cells in vitro induces a change in the genome-wide expression profile and inhibits gastric cancer cell growth. Cell Biol. Int. 34, 747–753 (2010).
Wang, J. et al. PTP1B expression contributes to gastric cancer progression. Med. Oncol. 29, 948–956 (2012).
Lessard, L. et al. PTP1B is an androgen receptor–regulated phosphatase that promotes the progression of prostate cancer. Cancer Res. 72, 1529–1537 (2012).
Zhu, S., Bjorge, J.D. & Fujita, D.J. PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res. 67, 10129–10137 (2007).
Johnson, K.J. et al. PTP1B suppresses prolactin activation of Stat5 in breast cancer cells. Am. J. Pathol. 177, 2971–2983 (2010).
Balavenkatraman, K.K. et al. Epithelial protein-tyrosine phosphatase 1B contributes to the induction of mammary tumors by HER2/Neu but is not essential for tumor maintenance. Mol. Cancer Res. 9, 1377–1384 (2011).
He, R., Zeng, L.F., He, Y., Zhang, S. & Zhang, Z.Y. Small molecule tools for functional interrogation of protein tyrosine phosphatases. FEBS J. 280, 731–750 (2013).
Kane, R.C. et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 12, 7271–7278 (2006).
Wiede, F. et al. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. J. Clin. Invest. 121, 4758–4774 (2011).
Tiganis, T. PTP1B and TCPTP—nonredundant phosphatases in insulin signaling and glucose homeostasis. FEBS J. 280, 445–458 (2013).
Galic, S. et al. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol. Cell. Biol. 25, 819–829 (2005).
Hanson, M.A. et al. A specific cholesterol binding site is established by the 2.8 Å structure of the human β2-adrenergic receptor. Structure 16, 897–905 (2008).
Zhang, J. et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501–506 (2010).
Hammoudeh, D.I., Follis, A.V., Prochownik, E.V. & Metallo, S.J. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J. Am. Chem. Soc. 131, 7390–7401 (2009).
Agulnik, M. et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J. Clin. Oncol. 25, 3978–3984 (2007).
Hinow, P., Wang, S.E., Arteaga, C.L. & Webb, G.F. Relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor. Theor. Biol. Med. Model. 4, 14 (2007).
Jänne, P.A., Taffaro, M.L., Salgia, R. & Johnson, B.E. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 62, 5242–5247 (2002).
Meng, T.C., Hsu, J.S.F. & Tonks, N.K. Development of a modified in-gel assay to identify protein tyrosine phosphatases that are oxidized and inactivated in vivo. Methods 35, 28–36 (2005).
Lin, G., Aranda, V., Muthuswamy, S.K. & Tonks, N.K. Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'. Genes Dev. 25, 1412–1425 (2011).
Acknowledgements
This research was supported by US National Institutes of Health (NIH) grants CA53840 and GM55989 and the Cold Spring Harbor Laboratory Cancer Centre Support Grant CA45508 to N.K.T.; by NIH grants GM100910 and GM098482, American Diabetes Association grant 1-14-ACN-31 and a Brown University Research Seed Fund grant by the Vice President for Research to W.P.; and by financial support from the French Agence Nationale de la Recherche (ANR) through ANR JCJC ProteinDisorder to M.R.J. and ANR MALZ TAUSTRUCT to M.B. J.K. is a fellow of the IDPbyNMR Marie Curie action of the European Commission (contract no 264257).
The 800-MHz NMR data were recorded at Brandeis University; the instrument was purchased with support from NIH S10-RR017269. NMR data (500 MHz and 850 MHz) were recorded in the Brown University Structural Biology Facility, which is generously supported by Brown University. N.K.T. is also grateful for support from the following foundations; The Gladowsky Breast Cancer Foundation, The Don Monti Memorial Research Foundation, Hansen Memorial Foundation, West Islip Breast Cancer Coalition for Long Island, Glen Cove CARES, Find a Cure Today (FACT), Constance Silveri, Robertson Research Fund and the Masthead Cove Yacht Club Carol Marcincuk Fund. PTP1B inhibitor MSI-1436 was provided by Ohr Pharmaceuticals and Genaera Corporation.
Author information
Authors and Affiliations
Contributions
N.K. performed the biochemical characterization of PTP1B inhibition by MSI-1436 and tested the effects of the inhibitor in cell and animal models; D.K., D.H.M., J.K., M.R.J., R.P., M.B. and W.P. designed, performed and analyzed NMR-based structural work. C.M.G. performed the homology modeling, molecular docking and dynamics simulation. B.X., S.D.A. and S.K.M. helped with the breast cancer studies. N.K., W.P. and N.K.T. analyzed the data and wrote the manuscript, which was reviewed by all authors. N.K.T. directed the study.
Corresponding author
Ethics declarations
Competing interests
A company called DepYmed Inc. was founded on 3 March 2014 with the primary purpose of taking MSI-1436 into the clinic in patients with HER2-positive breast cancer. It is owned equally by Ohr Pharmaceuticals and Cold Spring Harbor Laboratory. Authors N.K. and N.K.T. are entitled to a share based on the conditions of the Invention Agreement signed by all of the scientists at Cold Spring Harbor Laboratory.
Supplementary information
Supplementary Text and Figures
Supplementary Results, Supplementary Figures 1–22, Supplementary Tables 1–4 and Supplementary Note. (PDF 2493 kb)
Rights and permissions
About this article
Cite this article
Krishnan, N., Koveal, D., Miller, D. et al. Targeting the disordered C terminus of PTP1B with an allosteric inhibitor. Nat Chem Biol 10, 558–566 (2014). https://doi.org/10.1038/nchembio.1528
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.1528
This article is cited by
-
In Vitro Generated Equine Hepatic-Like Progenitor Cells as a Novel Potent Cell Pool for Equine Metabolic Syndrome (EMS) Treatment
Stem Cell Reviews and Reports (2023)
-
Inhibition of PTP1B by isosinensetin, a polymethoxylated flavone isolated from trifoliate orange peel: kinetic studies, molecular docking, and molecular dynamics simulation
Chemical Papers (2023)
-
The catalytic activity of TCPTP is auto-regulated by its intrinsically disordered tail and activated by Integrin alpha-1
Nature Communications (2022)
-
Protein tyrosine phosphatases in skeletal development and diseases
Bone Research (2022)
-
Trodusquemine: Potential Utility in Wound Regeneration
Regenerative Engineering and Translational Medicine (2022)